当前位置：
X-MOL 学术
›
J. Diabetes its Complicat.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk
Journal of Diabetes and its Complications ( IF 3 ) Pub Date : 2023-10-10 , DOI: 10.1016/j.jdiacomp.2023.108628 Robert Weingold 1 , Bernard Zinman 2 , Michaela Mattheus 3 , Anne Pernille Ofstad 4 , Dominik Steubl 5 , Christoph Wanner 6 , Silvio E Inzucchi 1
中文翻译：
恩格列净对 KDIGO CKD 风险群体的影响：在整个风险范围内，SGLT2 抑制对肾脏的保护作用
更新日期：2023-10-10
Journal of Diabetes and its Complications ( IF 3 ) Pub Date : 2023-10-10 , DOI: 10.1016/j.jdiacomp.2023.108628 Robert Weingold 1 , Bernard Zinman 2 , Michaela Mattheus 3 , Anne Pernille Ofstad 4 , Dominik Steubl 5 , Christoph Wanner 6 , Silvio E Inzucchi 1
Affiliation
T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62–0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30–1.86) in KDIGO risk category.
中文翻译：
恩格列净对 KDIGO CKD 风险群体的影响：在整个风险范围内，SGLT2 抑制对肾脏的保护作用
T2D 是 CKD 发生和进展的公认危险因素。KDIGO 建议根据进展为 ESKD 的可能性对风险进行分类。与安慰剂相比，恩格列净降低了 KDIGO 风险类别恶化的可能性（OR 0.70，95 % CI 0.62–0.78）并增加了改善的可能性（OR 1.56，95 % CI 1.30–1.86）。
京公网安备 11010802027423号